Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease

20 september 2026 bijgewerkt door: Fatima Yaman, Kutahya Health Sciences University

Changes in Specific miRNAs and Biochemical Biomarkers Following Personalized Cardiac Rehabilitation in Patients With Coronary Artery Disease

This prospective interventional study aims to investigate changes in specific microRNAs (miRNAs) and biochemical biomarkers following a personalized cardiac rehabilitation program in patients with coronary artery disease. A total of 46 participants aged 35-75 years who have undergone percutaneous coronary intervention or coronary artery bypass graft surgery and are eligible for cardiac rehabilitation will be included. Participants will complete a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Clinical assessments, cardiopulmonary exercise testing, and blood-based biomarker measurements will be performed before and after the rehabilitation program. The primary objective is to determine changes in miRNA and biochemical biomarker levels after cardiac rehabilitation and to evaluate the relationship between these changes and clinical improvement. The findings may contribute to a better understanding of biological responses to cardiac rehabilitation and support the development of more personalized rehabilitation strategies.

Studie Overzicht

Toestand

Nog niet aan het werven

Studietype

Ingrijpend

Inschrijving (Geschat)

46

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Kütahya, Turkije (Türkiye), 43020
        • Kutahya Health Sciences University
        • Contact:
        • Hoofdonderzoeker:
          • Fatima YAMAN, Assoc. Prof
        • Hoofdonderzoeker:
          • Meltem ÇOBAN, Dr.
        • Onderonderzoeker:
          • Merve AKDENİZ LEBLEBİCİER, Assoc. Prof
        • Onderonderzoeker:
          • Mevlüt DEMİR, Assoc. Prof
        • Onderonderzoeker:
          • Cansu OZBAYER, Prof. Dr.
        • Onderonderzoeker:
          • Fatih KAR, Assoc. Prof.

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

35 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Stable coronary artery disease
  • History of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Referred and considered clinically eligible for a structured cardiac rehabilitation program
  • Achievement of a respiratory quotient (RQ) of at least 1.0 during the baseline cardiopulmonary exercise test
  • Ability and willingness to participate in the study and complete the cardiac rehabilitation program

Exclusion Criteria:

  • Symptoms or signs of myocardial ischemia
  • Significant left ventricular outflow tract obstruction
  • Ventricular arrhythmia
  • Significant valvular heart disease
  • Uncontrolled hypertension
  • Severe comorbid conditions, including end-stage renal disease, advanced liver disease, or chronic inflammatory disease
  • Active malignancy
  • Physical limitations preventing full participation in exercise, including severe musculoskeletal disorders or major orthopedic or neurological comorbidities
  • Body mass index greater than 35 kg/m²
  • History of orthopedic surgery within the previous 6 months
  • Failure to comply with exercise testing or training procedures, or attendance of less than 80% of the rehabilitation program
  • Use of medications known to directly alter miRNA expression, such as certain immunosuppressive agents or chemotherapy drugs
  • Known psychiatric disorder
  • Presence of a permanent cardiac pacemaker

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Personalized Cardiac Rehabilitation Group

Participants will undergo a structured, individualized cardiac rehabilitation program lasting 6-8 weeks. Exercise intensity and workload will be prescribed according to each participant's baseline cardiopulmonary exercise test results, including peak oxygen uptake and maximal workload. The rehabilitation program will be tailored to the participant's clinical status and exercise capacity. Clinical assessments, cardiopulmonary exercise testing, and blood sampling for miRNA and biochemical biomarker analyses will be performed before and after completion of the rehabilitation program.

Participants will receive a structured, individualized cardiac rehabilitation program consisting of 30 supervised aerobic exercise sessions performed on a cycle ergometer. Each session will last approximately 45-60 minutes and will include a 5-10-minute low-intensity warm-up, an individualized aerobic exercise phase, and a gradual cool-down period. Exercise intensity will be prescribed according to baseline cardiopulmonary exercise testing and maximal exercise capacity. Training intensity will begin at approximately 40-50% of VO₂max, progress to 60-70% of VO₂max corresponding to a Borg Rating of Perceived Exertion of approximately 12-15, and may reach approximately 80% of VO₂max when clinically appropriate and well tolerated. Exercise workload will be individualized based on the maximal workload achieved during baseline cardiopulmonary exercise testing.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in miRNA Expression Levels
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in the expression levels of miR-21, miR-126, miR-92a, miR-1, miR-155, and miR-133a will be assessed using quantitative real-time polymerase chain reaction (qRT-PCR) before and after completion of the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Inflammatory, Cardiac, and Oxidative Stress Biomarkers
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Changes in circulating levels of NT-proBNP, troponins, hs-CRP, IL-6, TNF-α, ST2, semaphorins, MDA, ADMA, and eNOS will be assessed before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Peak Oxygen Uptake (VO₂max)
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Peak oxygen uptake will be assessed using cardiopulmonary exercise testing (CPET) performed on a cycle ergometer. VO₂max will be recorded in mL/kg/min as an indicator of maximal aerobic exercise capacity.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Exercise Workload
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum exercise workload achieved during cardiopulmonary exercise testing will be recorded in watts.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Six-Minute Walk Test Distance
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Functional exercise capacity will be assessed using the Six-Minute Walk Test. Participants will be instructed to walk as far as possible without running along a 30-meter corridor for six minutes. The total distance walked will be recorded in meters.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Resting Heart Rate
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Resting heart rate will be measured before cardiopulmonary exercise testing and recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Maximum Heart Rate
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Maximum heart rate achieved during cardiopulmonary exercise testing will be recorded in beats per minute.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program
Change in Health-Related Quality of Life
Tijdsspanne: Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36) before and after the cardiac rehabilitation program.

Baseline and immediately after completion of the 6-8-week cardiac rehabilitation program

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Vural KAVUNCU, Prof. Dr., Kutahya Health Sciences University

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

30 september 2026

Primaire voltooiing (Geschat)

31 december 2026

Studie voltooiing (Geschat)

1 februari 2027

Studieregistratiedata

Eerst ingediend

20 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

20 september 2026

Eerst geplaatst (Werkelijk)

25 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

20 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

"Individual participant data will not be shared because the study includes genetic and biomarker data that may raise privacy and confidentiality concerns."

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren